You are here:

olanzapine long acting injection (ZypAdhera)

Advice

following a full submission:

olanzapine long acting injection (ZypAdhera) is not recommended for use within NHS
Scotland.

Indication under review: Maintenance treatment of adult patients with schizophrenia
sufficiently stabilised during acute treatment with oral olanzapine.

The pivotal study showed comparable efficacy of olanzapine long-acting injection to oral
olanzapine in preventing relapse in stabilised patients over 24 weeks. Supervision
requirements in relation to the risk of post injection syndrome may limit the benefit of
decreased frequency of administration.

The manufacturer did not present a sufficiently robust economic case to gain acceptance by
SMC.

Drug Details

Drug Name: olanzapine long acting injection (ZypAdhera)
SMC Drug ID: 624/10
Manufacturer: Eli Lilly and Company Ltd
Indication: Maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine.
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 9 August 2010

Back